These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25327342)

  • 1. New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.
    Karasawa H; Pietra C; Giuliano C; Garcia-Rubio S; Xu X; Yakabi S; Taché Y; Wang L
    Neurogastroenterol Motil; 2014 Dec; 26(12):1771-82. PubMed ID: 25327342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Beneficial Effects of Ghrelin Agonist, HM01 on Homeostasis Alterations in 6-Hydroxydopamine Model of Parkinson's Disease in Male Rats.
    Minalyan A; Gabrielyan L; Pietra C; Taché Y; Wang L
    Front Integr Neurosci; 2019; 13():13. PubMed ID: 31031602
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.
    Wang L; Mogami S; Karasawa H; Yamada C; Yakabi S; Yakabi K; Hattori T; Taché Y
    Peptides; 2014 May; 55():136-44. PubMed ID: 24631952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats.
    Wang L; Murphy NP; Stengel A; Goebel-Stengel M; St Pierre DH; Maidment NT; Taché Y
    Neurogastroenterol Motil; 2012 May; 24(5):e235-45. PubMed ID: 22443313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site and mechanism of the colokinetic action of the ghrelin receptor agonist, HM01.
    Naitou K; Mamerto TP; Pustovit RV; Callaghan B; Rivera LR; Chan AJ; Ringuet MT; Pietra C; Furness JB
    Neurogastroenterol Motil; 2015 Dec; 27(12):1764-71. PubMed ID: 26416336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
    Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ghrelin agonist, HM01 activates central vagal and enteric cholinergic neurons and reverses gastric inflammatory and ileus responses in rats.
    Yuan PQ; Wu SV; Wang L; Taché Y
    Neurogastroenterol Motil; 2023 May; 35(5):e14561. PubMed ID: 36942655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of the Central versus Peripheral Gastrointestinal Prokinetic Activity of Two Novel Ghrelin Mimetics.
    Mohammadi EN; Pietra C; Giuliano C; Fugang L; Greenwood-Van Meerveld B
    J Pharmacol Exp Ther; 2019 Jan; 368(1):116-124. PubMed ID: 30377215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.
    Levandis G; Balestra B; Siani F; Rizzo V; Ghezzi C; Ambrosi G; Cerri S; Bonizzi A; Vicini R; Vairetti M; Ferrigno A; Pastoris O; Blandini F
    Neurogastroenterol Motil; 2015 Dec; 27(12):1783-95. PubMed ID: 26433214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
    Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
    Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis.
    Toti L; Travagli RA
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1013-23. PubMed ID: 25277799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
    Ndlovu BC; Daniels WM; Mabandla MV
    Neurotox Res; 2016 Jan; 29(1):126-34. PubMed ID: 26459303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Alachkar A; Brotchie JM; Jones OT
    J Mol Neurosci; 2012 Jan; 46(1):145-52. PubMed ID: 21562737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
    Song L; Yang X; Ma Y; Wu N; Liu Z
    Drug Des Devel Ther; 2014; 8():2173-9. PubMed ID: 25395834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The brain-penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion-induced emesis in Suncus murinus (house musk shrew).
    Tu L; Lu Z; Ngan MP; Lam FFY; Giuliano C; Lovati E; Pietra C; Rudd JA
    Br J Pharmacol; 2020 Apr; 177(7):1635-1650. PubMed ID: 31722444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The highly selective mGlu
    Hamadjida A; Sid-Otmane L; Kwan C; Frouni I; Nafade V; Bédard D; Gagnon D; Wallman MJ; Rouillard C; Parent A; Parent M; Huot P
    Eur J Neurosci; 2020 Jun; 51(12):2412-2422. PubMed ID: 31944461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.